IO Biotech, Inc. Common Stock
IOBT US4497781090
💰
Capitalization
Small-cap
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
🔗
Website
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -59% | -68% | -22% | -52% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
📊
Transactions
12
🙍
Insiders
7
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Hunter Heidi |
1.39 USD |
15,000 Bought |
20,885 USD |
30/05/2025 | 30/05/2025 |
| Hunter Heidi |
1.39 USD |
15,000 Bought |
20,885 USD |
30/05/2025 | 30/05/2025 |
| Smith Devin Whittemore SR OFF |
0.81 USD |
12,000 Bought |
9,720 USD |
23/12/2024 | 23/12/2024 |
| Sullivan Amy CFO |
0.83 USD |
10,250 Bought |
8,483 USD |
23/12/2024 | 23/12/2024 |
| Zocca Mai-britt CEO |
0.81 USD |
12,500 Bought |
10,120 USD |
23/12/2024 | 23/12/2024 |
| Ahmad Qasim Iftikhar CMO |
0.85 USD |
31,350 Bought |
26,553 USD |
23/12/2024 | 23/12/2024 |
| Novo Holdings A/s |
1.31 USD |
23,478 Sold |
30,787 USD |
25/07/2024 | 26/07/2024 |
| Novo Holdings A/s |
1.33 USD |
51,522 Sold |
68,339 USD |
25/07/2024 | 25/07/2024 |
| Novo Holdings A/s |
1.22 USD |
658,809 Sold |
802,495 USD |
10/05/2024 | 10/05/2024 |
| Novo Holdings A/s |
1.50 USD |
658,809 Sold |
988,411 USD |
09/02/2024 | 09/02/2024 |